NCT06312813 Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
| NCT ID | NCT06312813 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Wright State University |
| Condition | Rosacea |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2024-02-27 |
| Primary Completion | 2028-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 48 participants in total. It began in 2024-02-27 with a primary completion date of 2028-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Rosacea is a common skin condition associated with easy blushing and red face; many patients with rosacea react to sunlight with increased redness. The purpose of this study is to determine if the use of a topical medication will help reduce sunlight induced redness and irritation in patients with rosacea.
Eligibility Criteria
Inclusion Criteria: * Fitzpatrick Skin Type I - IIII * Self-identified rosacea or no history of flushing/blushing for controls * Able to provide medical history and list of medications -- control subjects will not be allowed to take medications that are known to be photosensitizers. Exclusion Criteria: * Using imipramine, amitriptyline or any other tricyclic antidepressant (oral or topical) * Using topical anti-inflammatory (within 1 week) or systemic agents (e.g. prednisone) * Large tattoos in the designated testing areas * Tanning bed use within last 3 months * Photodynamic Therapy or UCB treatments in past 3 months * Female Subjects: pregnant or nursing
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06312813 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rosacea. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06312813 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06312813 currently recruiting?
Yes, NCT06312813 is actively recruiting participants. Contact the research team at pturesearch@wrightstatephysicians.org for enrollment information.
Where is the NCT06312813 trial being conducted?
This trial is being conducted at Fairborn, United States.
Who is sponsoring the NCT06312813 clinical trial?
NCT06312813 is sponsored by Wright State University. The trial plans to enroll 48 participants.